Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1861P - Development and external validation of a novel TARGET-based prognostic nomogram for children with neuroblastoma

Date

16 Sep 2021

Session

ePoster Display

Presenters

Jiajian Hu

Citation

Annals of Oncology (2021) 32 (suppl_5): S1237-S1256. 10.1016/annonc/annonc701

Authors

J. Hu1, W. Kang2, F. Song2, Q. Zhao1

Author affiliations

  • 1 Pediatrcs Oncology, Tianjin Medical University Cancer Institute & Hospital, 300011 - Tianjin/CN
  • 2 Department Of Epidemiology And Biostatistics, Tianjin Medical University Cancer Institute & Hospital, 300000 - Tianjin/CN
More

Abstract 1861P

Background

The accuracy of the current staging systems, INPC histology categories and COG risk group, for predicting the overall survival of patients with neuroblastoma are still unsatisfactory. We aimed at developing a nomogram to accurately predict individual survival. This study sought to externally validate this nomogram using the Chinese cohort.

Methods

The records of 499 patients of neuroblastoma using the TARGET database's newest database with the publication time ranging from 2007 to 2015 were retrospectively analyzed. The nomogram was established by using prognostic factors determined by LASSO regression and the predictive accuracy was verified with the concordance index and the AUCs of ROC curves. Additionally, 155 patients of neuroblastoma, who were treated between 2011 and 2019 at our institute, were included as an external validation set.

Results

Gender, age, MYCN stage, INSS stage, diagnostic category and primary site were significant variables used to develop a nomogram for OS, which had a concordance index of 0.745 (95% CI, 0.700-0.790). The AUCs of ROC curves of 3-, and 5-year OS were 0.730 and 0.806. The calibration curved for the probability of postoperative 3-, and 5-year OS showed good agreement between the predicted and observed outcomes. The external validation showed the higher AUCs of ROC curves of 3-, 5-year OS were 0.840 and 0.824. Regard to the Chinese validation set, C-index (0.816 (95% CI, 0.747-0.885)) was also enhanced compared with the TARGET training set. Furthermore, according to the nomogram-predicted scores, the patients were respectively stratified into 2 and 3 groups with different risks to compared with the INPC histology categories and the COG risk group. The nomogram showed a better accuracy in predicting OS than the two current staging systems in K-M curves and AUC value.

Conclusions

Our nomogram based on TARGET database can predict the 3-, and 5-year OS of patients with NB and show satisfactory utility in Chinese clinical practice.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Tianjin Medical University Cancer Institute and Hospital.

Funding

The National Key R&D Program of China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.